Psoriasis Harbors Multiple Pathogenic Type 17 T-cell Subsets: Selective Modulation by Risankizumab 🔗 Access full article via Journal of Allergy and Clinical ImmunologyShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
